Akebia Therapeutics Grants Stock Options
Analysis based on 7 articles · First reported Jun 01, 2026 · Last updated Jul 02, 2026
The granting of stock options by Akebia Therapeutics to new employees is a routine corporate action. While it may slightly dilute existing shareholder value over time as options vest and are exercised, it is generally viewed positively as a tool for employee retention and attraction, which can contribute to the company's long-term growth and stability. The market impact is minimal given the relatively small number of shares involved.
Akebia Therapeutics, a biopharmaceutical company, granted stock options to newly-hired employees on two separate occasions. On June 30, 2026, Akebia Therapeutics granted options to 3 employees to purchase 125,600 shares at an exercise price of $1.14 per share. Previously, on May 29, 2026, Akebia Therapeutics granted options to one employee to purchase 8,400 shares at an exercise price of $1.02 per share. These grants were made as an inducement for employment and are in accordance with Nasdaq-100 Listing Rule 5635(c)(4). The options vest over four years and have a 10-year term.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard